Angiotensin II Receptor Antagonists-

Candesartan, Eposartan, Irbestan, Losartan metabolite, Olmestran, Telmistran, Valsartan 

Potassium supplements, potassum sparing diuretics,

NSAIDS, Lithium

Angiotensin II Receptor Antagonists-

Candesartan, Eposartan, Irbestan, Losartan metabolite, Olmesatran, Telmistran, Valsartan

OLMESATRAN

CNS -

Dizziness 3% ,Insomnia  >0.5%,  Headache >1% ,Fatigue > 0.5%

GI -

Diarrhea >1%,Dyspepsia/heartburn 0.5%,  Abdominal pain >0.5%     

Musculoskeletal- 

Arthalgia .0.5%  Pain >1%,   Myalgia > 0.5%

Respiratory - 

 Upper Res tract infn >1%  Sinusitis >1% Pharyngitis >1 Rhinitis >1%
 Influnz  symptoms >1% bronchitis>1%

Miscellaneous -

Chest pain > 0.5%  Rash > 0.5%  Tacycardia > 0.5%  Urinary tract infn > 0.5%
Peripheral edema   > 0.5%  Hypertriglyceridemia >1%
Creatinine phosphokinase increase  >1% Hyperglycemia >1%   Hematutia >1%
 Infected injury >1%

Pregnancy, lactation, billiary obstruction

Special precautions-

Intrmuscular volume depletion Conditions which stimulates rennin angiotensin aldersterone system.

Renovascular hypertension

Renal impairment and kidney transplantation

Hyperkalemia Aortic or mitral valve stenosis

Obstructive hypertropic cardiomyopathy Primary aldosteronism

Hepatic impairment

Excessive blood pressure decrease in patients with ischemic heart disease or ischemic cerbrovascular disease could result in myocardial infraction or stroke

Indication

Hypertension

Dosage

Hyperstension- 20mg once daily when used as monotherapy in patients who are not volume contracted

After 2 weeks  of therapy the dose of olmesartan may be increased to 40mg .

Doses above 40mg do not appear to have greater effect

Twice daily dosing offers no advantage over the same total dose given once daily

Angiotensin II Receptor Antagonists-

Candesartan, Eposartan, Irbestan, Losartan metabolite, Olmestran, Telmistran, Valsartan

 Pharmacology-

Olmesartan acheves blood pressure reduction in dose dependent manner thruough arterial vasodilation and reduced sodium retention

Pharmacokinetics-

Olmesartan showsl inear pharmcokinetics after single oral dose of upto 350mg and multiple oral doses of up to 80mg >The mean oral biavailability in healthy adult volunteers was 29% .

The median peak mean elmination half-lfe was approx 14-16 hrs. with a duraton of upto 24 hrs Olmesartan is not metabolised via the cytochrome P450 enzymes system and so is not affected by food nor it does affect drugs.

Olmersartan may be administered with or without food.